In the last year, Extrawell Pharmaceutical Holdings's Price has gone down from HK$0.25 to HK$0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will jump to HK$0.00 – up 100.00% from the current level. Looking ahead to five years, experts forecast that Fair Value will grow by 100.00%.

2026 Fair Value Forecast

HK$0.00

2027 Fair Value Forecast

HK$0.00

2028 Fair Value Forecast

HK$0.00

2029 Fair Value Forecast

HK$0.00

2030 Fair Value Forecast

HK$0.00

Extrawell Pharmaceutical Holdings Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Extrawell Pharmaceutical Holdings's Revenue has gone down from HK$77.58M to HK$72.58M – a 6.44% drop. In the next year, analysts predict that Revenue will jump to HK$74.25M – up 2.30% from the current level. Looking ahead to seven years, experts forecast that Revenue will grow by 3.22%.

2024 Rev Forecast

HK$0.07B

2025 Rev Forecast

HK$0.08B

2026 Rev Forecast

HK$0.08B

2027 Rev Forecast

HK$0.07B

2028 Rev Forecast

HK$0.07B

2029 Rev Forecast

HK$0.07B

2030 Rev Forecast

HK$0.07B

Extrawell Pharmaceutical Holdings Dividend per Share Forecast for 2023 - 2025 - 2030

Extrawell Pharmaceutical Holdings Free Cash Flow Forecast for 2023 - 2025 - 2030

Extrawell Pharmaceutical Holdings EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, EBITDA for Extrawell Pharmaceutical Holdings has grown by 111.42%, going from HK$-2.19M to HK$-4.63M. 0 analysts predict Extrawell Pharmaceutical Holdings's EBITDA will decrease by 13.51% in the next year, reaching HK$-4.00M. Over the next seven years, experts anticipate that EBITDA growth for Extrawell Pharmaceutical Holdings will be 2.22%.

2024 EBITDA Forecast

HK$-4004641.33

2025 EBITDA Forecast

HK$-4410578.48

2026 EBITDA Forecast

HK$-5067019.57

2027 EBITDA Forecast

HK$-4956558.55

2028 EBITDA Forecast

HK$-4627277.84

2029 EBITDA Forecast

HK$-4571596.26

2030 EBITDA Forecast

HK$-4732668.84

Extrawell Pharmaceutical Holdings EBIT Forecast for 2023 - 2025 - 2030

Extrawell Pharmaceutical Holdings's EBIT has grown in the last three years, jumping from HK$-8.08M to HK$-11.28M – an increase of 39.60%. For the following year, the 0 analysts predict that Extrawell Pharmaceutical Holdings's EBIT will drop by 8.98%, reaching HK$-10.27M. In 2030, the professionals' prediction is that 858's EBIT will decrease by 2.44%, reaching HK$-11.01M.

2024 EBIT Forecast

HK$-10266680.00

2025 EBIT Forecast

HK$-10560649.27

2026 EBIT Forecast

HK$-11328408.47

2027 EBIT Forecast

HK$-11340114.49

2028 EBIT Forecast

HK$-10974962.81

2029 EBIT Forecast

HK$-10845092.41

2030 EBIT Forecast

HK$-11005238.28

Extrawell Pharmaceutical Holdings EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last year, Extrawell Pharmaceutical Holdings's EPS has gone down from HK$0.04 to HK$0.00 – a 100.00% drop. In the next year, analysts predict that EPS will jump to HK$0.00 – up 100.00% from the current level. Looking ahead to five years, experts forecast that EPS will grow by 100.00%.

2026 EPS Forecast

HK$0.00

2027 EPS Forecast

HK$0.00

2028 EPS Forecast

HK$0.00

2029 EPS Forecast

HK$0.00

2030 EPS Forecast

HK$0.00